1. Scrip
  2. >>Leadership

Pfizer Picks Boshoff To Head R&D, A Smooth Transition In An Uncertain Time

 
• By Jessica Merrill

Chris Boshoff has been with Pfizer more than 10 years and has led oncology R&D and the integration of Seagen. He will succeed Mikael Dolsten, who will depart after leading R&D for nearly 15 years.

(Shutterstock)
Key Takeaways
  • Pfizer oncology drug leader Chris Boshoff will lead R&D following the departure of Mikael Dolsten.

Pfizer has picked insider and oncology drug leader Chris Boshoff to oversee research and development as chief scientific officer and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.